Results 11 to 20 of about 289,605 (341)
International Journal of Breast Cancer, 2012 Ever since the seminal work that was published by Perou et al., triple-negative breast cancer (TNBC) has become a common lexicon among clinicians who care for patients with breast cancer. Beside portending a poor outcome, TNBC is unique in that, unlike the hormone-positive and Her-2-positive cancer cells, it lacks target specific therapy.
Quyen D. Chu, Tari King, Thelma Hurd
doaj +8 more sources
Asian Pacific Journal of Cancer Prevention, 2014 Triple-negative breast cancers (TNBC), characterized by absence of the estrogen receptor (ER) and progesterone receptor (PR) and lack of overexpression of human epidermal growth factor receptor 2 (HER2), have a poor prognosis. To overcome therapy limitations of TNBC, various new approaches are needed.
Idil, Cetin, Mehmet, Topcul
+9 more sources
Male Triple-Negative Breast Cancer [PDF]
Cureus, 2021 Male breast cancer is a rarely encountered disease, when compared with female breast cancer, often detected in more advanced stage at the time of diagnosis, and associated with more lymph node metastasis rates, more estrogen receptors positivity, and less human epidermal growth factor receptor-2 expression (HER-2) rates.
Qavi, Qasif +4 more
openaire +2 more sources
Triple Negative Breast Cancer [PDF]
Klinicka onkologie, 2015 In the Czech Republic, around 6,500 women get breast cancer each year; out of this number, nearly 1,000 women are triple negative subtype. Triple negative breast cancer is characterized by lack of expression of α-estrogen, progesterone, and HER2 receptors.
J, Navrátil +5 more
openaire +2 more sources
Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas. [PDF]
PLoS ONE, 2012 BackgroundTriple-negative breast cancer is a subtype of breast cancer with aggressive tumor behavior and distinct disease etiology. Due to the lack of an effective targeted medicine, treatment options for triple-negative breast cancer are few and ...
Wen-Hung Kuo +6 more
doaj +1 more source
Immune Effect of Active Components of Traditional Chinese Medicine on Triple-Negative Breast Cancer
Frontiers in Pharmacology, 2021 Triple-negative breast cancers are heterogeneous, poorly prognostic, and metastatic malignancies that result in a high risk of death for patients. Targeted therapy for triple-negative breast cancer has been extremely challenging due to the lack of ...
Wenjie Zhao +8 more
doaj +1 more source
Recent advances in therapeutic strategies for triple-negative breast cancer
Journal of Hematology & Oncology, 2022 Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however, a proportion of patients have missed the ...
Yun-Rui Li +6 more
semanticscholar +1 more source
Research progress of single-cell sequencing in neoadjuvant chemotherapy for triple-negative breast cancer [PDF]
Zhongguo aizheng zazhi, 2021 Triple-negative breast cancer is the most invasive and malignant type of breast cancer. At present, therapy for triple-negative breast cancer is the comprehensive treatment regimens based on chemotherapy, in which neoadjuvant chemotherapy plays an ...
HU Xi’e , YANG Zhenyu , XUE Jingyi , YANG Ping , PENG Shujia , YUAN Lijuan , BAO Guoqiang
doaj +1 more source
World Journal of Surgical Oncology, 2020 Background Metaplastic breast cancer remains poorly characterized given its rarity and heterogeneity. The majority of metaplastic breast cancers demonstrate a phenotype of triple-negative breast cancer; however, differences in clinical outcomes between ...
Evan Morgan +18 more
doaj +1 more source
Spatial predictors of immunotherapy response in triple-negative breast cancer
Nature, 2023 Immune checkpoint blockade (ICB) benefits some patients with triple-negative breast cancer, but what distinguishes responders from non-responders is unclear^ 1 .
Xiao Qian Wang +26 more
semanticscholar +1 more source